Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis
A 43-year-old Japanese woman with rheumatoid arthritis treated by infliximab and methotrexate for 11 years was admitted for proteinuria and purpura. A kidney biopsy revealed endothelial damage-dominant nephritis with IgA deposition. Infliximab and methotrexate were discontinued, and tocilizumab was started; however, proteinuria persisted. Therefore, tocilizumab was discontinued, and oral prednisolone and methylprednisolone pulse therapy were administered. After 6 months, urinary protein was less than 0.1 g/day, and purpura subsided. To our knowledge, this is the first case of endothelial damage-dominant nephritis related to IgA vasculitis involving the skin and kidney after long-term use of infliximab and methotrexate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 62(2023), 1 vom: 01. Jan., Seite 81-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fukuda, Makoto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B72HH48FLU |
|---|
| Anmerkungen: |
Date Completed 05.01.2023 Date Revised 03.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.9059-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341721190 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341721190 | ||
| 003 | DE-627 | ||
| 005 | 20231226012427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.9059-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341721190 | ||
| 035 | |a (NLM)35650123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fukuda, Makoto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endothelial Damage-dominant Nephritis Related to IgA Vasculitis after 11 Years' Use of Infliximab for Rheumatoid Arthritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2023 | ||
| 500 | |a Date Revised 03.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 43-year-old Japanese woman with rheumatoid arthritis treated by infliximab and methotrexate for 11 years was admitted for proteinuria and purpura. A kidney biopsy revealed endothelial damage-dominant nephritis with IgA deposition. Infliximab and methotrexate were discontinued, and tocilizumab was started; however, proteinuria persisted. Therefore, tocilizumab was discontinued, and oral prednisolone and methylprednisolone pulse therapy were administered. After 6 months, urinary protein was less than 0.1 g/day, and purpura subsided. To our knowledge, this is the first case of endothelial damage-dominant nephritis related to IgA vasculitis involving the skin and kidney after long-term use of infliximab and methotrexate | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IgA vasculitis | |
| 650 | 4 | |a endocapillary glomerulonephritis | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a tocilizumab | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Sawa, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Ikuma, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Oba, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuno, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamanouchi, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Sekine, Akinari |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Eiko |e verfasserin |4 aut | |
| 700 | 1 | |a Suwabe, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Hoshino, Junichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kono, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Kinowaki, Keiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohashi, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Tamaki, Hiromichi |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazono, Motoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Ubara, Yoshifumi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 62(2023), 1 vom: 01. Jan., Seite 81-85 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:81-85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.9059-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 1 |b 01 |c 01 |h 81-85 | ||